W. Mike Heath ASHP Federal Forum

(1-001) Enhancing Revenue for Clinical Pharmacy Services in the Indian Health Service

(1-002) Formation of an Outpatient Ketamine Infusion Clinic at the Cheyenne Veteran's Affairs Health Care System

(1-003) Matchmaker Metrics: Streamlining PGY-1 Pharmacy Residency Selections for Optimal Outcomes

(1-004) Optimizing Inventory Management Strategies in Outpatient Pharmacy Operations: A Comprehensive Analysis

(1-006) An Evaluation of Continuous Glucose Monitoring System Management by PACT Pharmacists in the Primary Care Setting

(1-007) Analysis of Adverse Drug Reactions Associated with Intravenous Iron Infusion Formulations in the Veterans Health Administration

(1-008) The effect of a prescribing protocol to manage patients with type II diabetes who are referred to a pharmacist-run clinic at a tribal health system

(1-009) Assessing screening practices for metabolic dysfunction-associated steatotic liver disease (MASLD) in Type II Diabetes Mellitus (T2DM) at Federal Health Center (FHCC) primary care clinics.

(1-010) Assessment of veterans diagnosed with acute kidney injury while on empagliflozin

(1-011) Cardiovascular Risk Reduction Using Statins in Patients with Type 2 Diabetes Mellitus at a Rural Veterans Affairs Healthcare System

(1-012) Changes in Type 2 Diabetes Medication Management with Utilization of CGM in the Primary Care Setting at Orlando Veterans Affairs Healthcare System (OVAHCS)

(1-013) Clinical Pharmacist Interventions in Veterans Enrolled in Veteran Affairs Caribbean Healthcare Systems (VACHS) MOVE! Weight Management Program Receiving Glucagon-Like Peptide-1 Receptor Antagonists (GLP1-RAs)

(1-014) Comparison of Indicated Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Outcomes in the Veteran Population

(1-015) Crow Service Unit Asthma Control in Tribal Communities Pilot Initiative: Implementing Single Maintenance and Reliever Therapy in American Indians/Alaskan Natives with Asthma

(1-016) De-escalation of Inhaled Corticosteroids and Optimization of Guideline Directed Medical Therapy (GDMT) in Patients with Chronic Obstructive Pulmonary Disease

(1-017) Deprescribing of Sulfonylureas in Older Adults with Well-Controlled Type 2 Diabetes at VA Salt Lake City Health Care System

(1-018) Deprescribing Sulfonylureas in Patients Over the Age of 65 within the Boise VA Medical Center

(1-019) Effect of a formulary change from budesonide/formoterol to fluticasone/salmeterol on chronic obstructive pulmonary disease control among Veterans at the Veterans Affairs Maryland Health Care System

(1-020) Effect of Provider Education on COPD Prescribing Trends within a Federal Health Care Center

(1-021) Effects of Pharmacist Led De-escalation of Inhaled Corticosteroid Use in Veterans with Chronic Obstructive Pulmonary Disease.

(1-022) Enhancing Patient-Reported Weight Documentation: Impact of Educational Interventions on Weight Management Providers at Minneapolis Veterans Affairs Health Care System (MVAHCS)

(1-023) Enhancing the Utilization of Sodium-Glucose Cotransporter-2 Inhibitors in Rural Diabetic Veterans with Chronic Kidney Disease at Veteran Affairs Community-Based Outpatient Clinics in Central Iowa

(1-024) Evaluate Patient Satisfaction Through the Implementation of a Clinical Pharmacist Practitioner-Led Neurology Clinic

(1-025) Evaluating Discordance Between Hemoglobin A1c and Glucose Management Indicator in Patients with Diabetes and Chronic Kidney Disease

(1-026) Evaluating the Effects of Suicidal Ideation Counseling for Patients Beginning Antidepressant Treatment

(1-027) Evaluating the Impact of a Pharmacist-Run Gout Clinic in a VA Community Based Outpatient Clinic

(1-028) Evaluating the Impact of Early Follow-up on A1C Reduction After Initial Diabetes Specialist Consultation

(1-029) Evaluating the Impact of Pharmacogenomics Testing on Patient Care Outcomes: A Review of Veterans in the Montana VA Health Care System (MTVAHCS)

(1-030) Evaluating the Impact of Sulfonylurea Deprescribing in Hypoglycemia

(1-031) Evaluation of a Clinical Pharmacist-Led Weight Loss Clinic in an Outpatient Veterans Affairs Population

(1-032) Evaluation of Ambulatory Alcohol Detoxification Standard Operating Procedure Implementation

(1-033) Evaluation of blood pressure medication requirements after semaglutide initiation for weight loss

(1-034) Evaluation of interventions from pharmacist-led chronic kidney disease (CKD) focused clinic

(1-035) Evaluation of Interventions Made Following Hypoglycemia in a Veteran Population

(1-036) Evaluation of Patient Aligned Care Team Clinical Pharmacist Practitioner Interventions on Gout Management

(1-037) Evaluation of Pharmacist-Driven Statin Prescribing and Adherence Monitoring in Female Veterans

(1-038) Evaluation of prescribing of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic (GIP)/GLP-1 RAs in Veterans with type II diabetes and fatty liver disease

(1-039) Evaluation of Semaglutide Prescribing Practices in Patients for Weight Loss at the Boise VA Medical Center (VAMC)

(1-040) Evaluation of the Current Endocrinology Community Care Process at a Single Veterans Health Care System

(1-041) Evaluation of the Impact of a Clinical Pharmacist on Primary Care Outcomes in a Behavioral Health Clinic

(1-042) Evaluation of the Outpatient Prescribing of Sodium Glucose Co-transporter 2 Inhibitors at a Veterans Affairs Medical Center

(1-043) Evaluation of Veterans Affairs Patient-Aligned Care Team Clinical Pharmacist Practitioner Interventions in Chronic Obstructive Pulmonary Disease

(1-044) Evaluation of weight loss effects of semaglutide and patient adherence with the Weight Management Program for Veterans

(1-045) Identifying Patients at High Risk for Peripheral Artery Disease using Ankle-Brachial Index in Pharmacist-Led Screening Clinic

(1-046) Impact of a Patient-Aligned Care Team (PACT) Clinical Pharmacist Practitioner (CPP) on Patient Outcomes at the VA Maine Healthcare System

(1-047) Impact of a Shared Medical Appointment (SMA) for Cardiovascular Health Outcomes Within the Veterans Health Administration

(1-048) Impact of Clinical Pharmacists Intervention on COPD Outcomes

(1-049) Impact of Continuous Glucose Monitoring Systems on Glycemic Control in Patients with Type 2 Diabetes Mellitus

(1-050) Impact of Continuous Glucose Monitors on De-escalation of Diabetic Therapy in a Veteran Population

(1-051) Impact of Pharmacist Education on Continuous Glucose Monitor Prescribing in a Veteran Population

(1-052) Impact of Pharmacist Interventions on Chronic Obstructive Pulmonary Disease Exacerbations Among Patients at a Rural Veterans Affairs Hospital

(1-053) Impact of Pharmacist-Led Care on Diabetes Management Outcomes

(1-054) Impact of Real-Time Continuous Glucose Monitoring (rtCGM) on Glycemic Control and Hypoglycemia in Various Subpopulations

(1-055) Impact of semaglutide intervention in a pharmacist-managed dyslipidemia clinic

(1-056) Implementation of a Pain Order Menu and the Effects on Pain Management Prescribing within a VA Health System

(1-057) Implementation of a Pharmacist-Led Weight Loss Clinic at an Indian Health Service Facility

(1-058) Implementing a Healthy Heart Shared Medical Appointment (SMA) to Improve Lipid Outcomes and Increase Utilization of Statin Therapy in the Veteran Population

(1-059) Implementing Continuous Glucose Monitor Group Education Classes for Veterans led by Clinical Pharmacist Practitioners at the Veterans Affairs Central Ohio Healthcare System

(1-060) Improving Anatomy-Specific Screening for Transgender and Gender Diverse Veterans at the Minneapolis VA Health Care System (MVAHCS)

(1-061) Improving SGLT2 Inhibitor Utilization in Chronic Kidney Disease Patients with or without Diabetes: A Quality Improvement Initiative

(1-062) Initiation of a Comprehensive Medication Management Clinic for Patients with Complex Medication Regimens, Polypharmacy, or Recent Transition of Care

(1-063) Long-term Glycemic Control with the Use of Continuous Glucose Monitors in Veterans with Type 2 Diabetes

(1-064) Optimizing A1c Outcomes in Veterans: Evaluating Compliance to Dexcom G7 CGMs and Data Sharing Methods at a Veterans Affairs Medical Center (VAMC)

(1-065) Optimizing Outpatient Heart Failure Management through Sodium Glucose Co Transporter 2 (SGLT2) Inhibitor Initiation using the Federal Electronic Health Record (EHR) Dashboard

(1-066) Outcomes of Pharmacist-Led Weight Loss Management in Patients Using Semaglutide (Wegovy)

(1-067) Pharmacist-Led Deprescribing of Inappropriately Prescribed Inhaled Corticosteroids in Veterans with Chronic Obstructive Pulmonary Disease

(1-068) Pharmacist-Led Optimization of Sodium-Glucose Cotransporter-2 inhibitors in Veterans with Chronic Kidney Disease and Type 2 Diabetes Mellitus at the Carl Vinson VA Medical Center

(1-069) Pharmacogenomics-Guided Strategies to Improve Statin Therapy Acceptance and Initiation

(1-070) Pharmacy-based Interventions for Diabetic Patients on Canagliflozin with Impaired Renal Function

(1-071) Real-World incidence of pancreatitis when prescribed Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in a Veteran population

(1-072) Real-world Incidence of Thyroid Cancer when Prescribed Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in a Veteran Population

(1-074) Reducing the Risk of Hypoglycemic Events through Targeted Interventions Focused on Veterans at High Risk

(1-075) Retrospective Analysis of the Impact of Pharmacist Phone Appointments versus Face-to-Face Appointments on Veterans Reaching Glycemic Goals

(1-076) Semaglutide clinical outcomes in Native American patients at the Albuquerque Indian Health Center: A retrospective observational study

(1-077) Standardization of Protocols for Outpatient Management of Acute Hypoglycemia in a Veterans Affairs Medical Center

(1-078) Strategies for Maintaining Incretin Mimetic Therapy for Weight Management During Drug Shortages at a VA Medical Center

(1-079) Suicide-Related Events when using Glucagon Like Peptide 1 Receptor Agonists in a Veteran Population with a History of Mental Health Conditions

(1-080) The Effect of PACT CPP Targeted Population Health Management in Improving Health Equity for Statin Use in Women Veterans with ASCVD.

(1-081) The effects of clinical pharmacist management of type two diabetes using continuous glucose monitors on A1c at the Boise VA Medical Center

(1-082) The Impact of Clinical Pharmacist Collaboration with Primary Care Teams at a Community Based Outpatient Clinic (CBOC)

(1-083) Tolerability and Effects of Discontinuation of Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and Glucagon-like peptide-1 / Gastric inhibitory polypeptide receptor agonist (GLP-1/GIP RA)

(1-084) Utilizing the Primary Care Equity Dashboard to Target Statin Prescribing in Female Veterans with Diabetes.

(1-085) VA Puget Sound HTN Pathway Equity Analysis

(1-086) Veteran Outcomes after Implementing Methods to Optimize Continuous Glucose Monitoring (CGM) Prescribing and Education

(1-087) Anticoagulation Stewardship: Enhancing Upper Gastrointestinal Bleed Risk Management in Veterans on Concomitant Anticoagulant and Antiplatelet Therapy Through Risk Stratification and Workflow Optimization

(1-088) Aspirin versus Direct Oral Anticoagulants for Thromboprophylaxis after Total Knee and Hip Arthroplasty

(1-089) Assessing Heparin Infusion Initiation and Adjustment for Elevated Baseline Anti-Xa Levels in Hospitalized Veterans: A Quality Improvement Project in a VA Healthcare System

(1-090) Assessing the Effectiveness of the Miami Veterans Affairs Transitions of Care Program: Patient Follow-Up with Pharmacists for Anticoagulation Management After Hospital Discharge

(1-091) Characterization and Clinical Outcomes of Inappropriate Direct Oral Anticoagulant Dosing in Atrial Arrhythmia

(1-092) Comparison of Recurrent Venous Thromboembolism Rates in Patients With a History of Bariatric Surgery on Warfarin Compared to Rivaroxaban or Apixaban

(1-093) Effect of Prescribing Metoprolol Succinate Versus Carvedilol Therapy on Administration of Other Guideline Directed Therapy for Heart Failure with Reduced Ejection Fraction

(1-094) Evaluating the Impact of Implementation of Pharmacist Led Clinic on Antiarrhythmic Monitoring at a Rural Veterans Affairs Hospital

(1-095) Evaluating the Use of Sodium-Glucose Co-Transport 2 Inhibitors in Veterans with Heart Failure Preserved Ejection Fraction

(1-096) Evaluation of Anticoagulation Reversal Protocols at a Veterans Affairs Medical Center

(1-097) Evaluation of Dofetilide and Sotalol Protocol Deviations During Inpatient Hospitalization

(1-098) Evaluation of Guideline-Directed Medical Therapy in Heart Failure with Preserved Ejection Fraction at VA Greater Los Angeles Heart Failure Clinics

(1-099) Evaluation of Iron Deficiency Status in Patients Admitted with Acute Decompensated Heart Failure

(1-100) Evaluation of PCKS9 Inhibitor Adherence within a Veterans Affairs Cohort

(1-101) Evaluation of Semaglutide in Heart Failure patients with preserved Ejection Fraction with Type 2 Diabetes and/or Obesity Readmitted in 90 days post Heart Failure hospitalization

(1-102) Evaluation of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Initiation in Veterans Discharged Nationally After Acute Decompensated Heart Failure

(1-103) Evaluation of Treatments for Atrial Fibrillation Prior to Intensive Care Unit Admission

(1-104) Implementation of a Pharmacy-Managed Dofetilide Monitoring Program at VA Maine Healthcare System

(1-105) Integration of Pharmacist-Led Heart Failure Recommendations During Hospitalization

(1-106) Medication Use Evaluation (MUE) Project on Aspirin Utilization in Patients with Atrial Fibrillation on Apixaban

(1-107) Optimization of guideline-directed medical therapy (GDMT) in veterans with an acute heart failure reduced ejection fraction (HFrEF) exacerbation prior to hospital discharge

(1-108) Outpatient Initiation of Sotalol

(1-109) Pharmacist Interventions for Patients with Heart Failure via Home Telehealth

(1-110) Quality Improvement Evaluation of Periprocedural Anticoagulation Management at the Miami Veterans Affairs Healthcare System

(1-111) Stroke Prevention in Atrial Fibrillation/Flutter - Identifying Health Disparities in Anticoagulation Prescribing Practices - At VA Sierra Nevada Medical Center

(1-112) Safety and Efficacy of Direct Oral Anticoagulants in Veterans with Obesity

(1-113) Evaluating the Appropriate Use of Continuous Glucose Monitoring Systems (CGMS) for Clinical Outcomes

(1-114) Evaluation of COPD Exacerbations Management and Hospital Discharge at VA Caribbean Healthcare System

(1-115) Impact of Hemoglobin A1c in Well Controlled Diabetes Patients Two Years after Discharge from a Pharmacist-Led Diabetes Clinic

(1-116) Impact of Semaglutide on Retinopathy Progression and HbA1c Control in Veterans with Type 2 Diabetes Mellitus: A Follow-up Study

(1-117) Development and Implementation of Clinical Pharmacy Symposium at an Academic, County Health System — Phase 1

(1-118) Clinical Decision Support System Implementation: Clinical Pharmacy Practitioner Perspectives and Changes in Practice

(1-119) Clinical Impact of Timely Follow-Up Post-Discharge for Veterans with Heart Failure

(1-120) Constructing a Veteran-oriented Outcomes Survey for Pharmacist-Led Centralized Specialty Medication Management Using Cognitive Interviews

(1-121) Evaluation and Assessment of a Heart Failure with reduced Ejection Fraction (HFrEF) Transitions of Care Process at James A Haley Veterans’ Hospital and Clinics (JAHVH)

(1-122) Evaluation of Current Warfarin and Critical Drug-Drug Interactions Local Policy at Central Alabama Veterans Health Care System

(1-123) Expanding the Role of Pharmacy Residents During Weekend Staffing: Intravenous to Oral Conversions

(1-124) Frequency of Vitamin B12 monitoring for Patients on Metformin

(1-126) Improving Transitions of Care Processes at a Tribal Health Care Facility to Reduce Readmissions

(1-127) Integrating a comprehensive pharmacist-led weight loss initiative with semaglutide into the Pharmacy Primary Care Clinic at Red Lake Hospital

(1-128) Local Implementation of Guidance for Managing Scarce Weight Management Medication Resources at a Single VA

(1-129) Rate of Follow-up on Empiric Antibiotics Based on Culture and Sensitivity Results for the Treatment of a Urinary Tract Infection

(1-130) Utilization of Patient Aligned Care Team Clinical Pharmacist Practitioners to decrease Endocrinology Community Care Consults

(1-131) Appropriate Timing of Medication Administration to Optimize Treatments in Patients Receiving Hemodialysis

(1-132) Blood Glucose Management Using Insulin Glargine (Lantus) Versus the Biosimilar Insulin Glargine-yfgn

(1-133) Effect on length of stay upon administration of high-dose steroids at a Level II Veterans Affairs Medical Center

(1-134) Evaluation of Hospital Admissions for Diabetic Ketoacidosis Following the Initiation of Empagliflozin in a Veteran Population

(1-135) Evaluation of Insulin Dose Adjustments after Initiation of GLP-1 Receptor Agonist in Patients with Insulin-Dependent Type 2 Diabetes

(1-136) Gonadotropin-Releasing Hormone (GnRH) Agonist Monitoring for Transgender Veterans at VA Sierra Nevada Health Care System

(1-137) Metabolic Effects of Low-Dose Quetiapine in a Veteran Population

(1-138) Optimizing Chronic Pain Control: A Pharmacist-Driven Approach to Reducing Opioid Use and Initiating Buprenorphine in Patients at a High Risk for Adverse Events and Mortality

(1-139) Stress Ulcer Prophylaxis in Hospital Settings: Striking the Right Balance

(1-140) Timing of Postoperative Beta Blocker Administration and Incidence of Postoperative Atrial Fibrillation in Veterans Undergoing Coronary Artery Bypass Surgery

(1-141) Efficacy of glucagon-like peptide-1 receptor agonists for weight loss in people with obesity

(1-142) Scheduling Prescription Fills to Optimize Workflow for Coordinated Care Patients in an Outpatient Pharmacy

(1-143) Reimplementation of a Pharmacist-Centered Contingency Management (CM) Service – Current Challenges and Expansions to the Program

(1-144) Utilization of Battlefield Acupuncture by Clinical Pharmacists as a Complimentary Medicine Approach for Pain Management: a Retrospective Cohort Study

(1-145) Innovative Sterile Compounding for Complex Cases: Crafting Ophthalmic Compound Recipes

(1-146) Evaluation of Medication Regimens Following Hyperglycemic Crisis in Veterans with Type 2 Diabetes Mellitus

(1-147) Facility-level initiation of empagliflozin during hospitalization and at discharge for eligible patients admitted for acute decompensated heart failure

(1-148) Impact of Clinical Pharmacy Practitioner on SGLT2i Prescribing Rates in Female Veterans with T2DM and CKD

(1-149) Increasing Utilization of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Veterans with Chronic Kidney Disease and Type 2 Diabetes Mellitus at James A. Haley Veterans’ Hospital (JAHVH)

(1-150) Appropriateness of Naltrexone Monthly Long-Acting Injection Prescribing Since the Prior Authorization Drug Request Requirement Removal at the Columbia Veterans Affairs Health System

(1-151) Appropriateness of Varenicline Prescribing at Columbia Veterans Affairs Healthcare System Following Prior Authorization Drug Request Removal

(1-152) Assessing the tolerability of sacubitril/valsartan in Veterans with Heart Failure with Reduced Ejection Fraction

(1-153) Assessing the utilization of topiramate for the off-label indication of alcohol use disorder treatment at the Veteran Affairs Healthcare System

(1-154) Comparison of Weight Loss Medications Outcomes in a Veteran Population

(1-155) Evaluating the Use of Paroxetine in an Elderly Veteran Population

(1-156) Evaluation of appropriate prescribing of continuous glucose monitors by providers in a Veterans Affairs Healthcare System

(1-157) Evaluation of Catheter-Associated Asymptomatic Bacteriuria and Urinary Tract Infection Management within a Veterans Affairs Healthcare System Home-Based Primary Care Program

(1-158) Evaluation of COPD Inhaler Therapy in Veterans: A Retrospective Study Assessing Adherence to 2023 Gold Guidelines at Robert J. Dole VA Medical Center

(1-159) Evaluation of liposomal bupivacaine versus standard anesthesia on postoperative pain control and opioid requirements: a retrospective cohort study

(1-160) Evaluation of Osteoporosis, Risk, Screening, and Treatment in a Veteran Affairs Community Living Center

(1-161) Evaluation of Outpatient Vaccine Administration

(1-162) Evaluation of Proton-Pump Inhibitor Use and Rate of Reassessment in Older Adults at the Providence Veterans Affairs Healthcare System

(1-163) Evaluation of Semaglutide for Type 2 Diabetes Mellitus and/or weight loss in an ambulatory care setting

(1-164) Evaluation of the Treatment of Neuropathic Pain at the Boise VA Medical Center

(1-165) Impact of Standardized, Guideline-Driven Instructions and Assessing Provider Prescribing Barriers for Budesonide/Formoterol in Asthma Management: A Quality Improvement Initiative within the Nuka System of Care

(1-166) Medication Use Evaluation for Oral Ciprofloxacin in a Veterans Affairs Healthcare System

(1-167) Medication Use Evaluation of Atypical Antipsychotic Augmentation for Treatment - Resistant Depression in Veterans: Retrospective Assessment of Utilization

(1-168) Medication Use Evaluation of High Dose Vitamin D (ergocalciferol or Cholecalciferol) for Vitamin D Deficiency in a Veterans Affairs Healthcare System

(1-169) Optimization of antibiotic therapy for community-acquired intra-abdominal infections after implementation of a treatment algorithm

(1-170) Triptan Prescribing in Cardiovascular or Cerebrovascular Disease

(1-171) Assessment of Empiric Antimicrobial Prescribing for Cystitis in Patients Discharged from the Oklahoma City Veterans Affairs Health Care System Emergency Department

(1-172) Effectiveness and Safety of Droperidol Use in the Veterans Affairs Greater Los Angeles Healthcare System (VAGLA) Emergency Department

(1-173) Emergency Room Visits for Uncontrolled Pain in Veterans on Chronic Long-Term Opioid Therapy: Traditional Opioid Agonists vs. Buprenorphine

(1-174) Evaluation of 30-day Emergency Department Return Rates Based on Injectable Pain Medications

(1-175) Impact of Intravenous Push (IVP) Antibiotics on Sepsis Management at a Veterans Affairs Medical Center Emergency Department

(1-176) Increasing Naloxone Dispensing for At Risk Patients Discharging from Veterans Health Administration Puget Sound Emergency Department

(1-177) Treatment of Cyclic Vomiting Syndrome and Cannabinoid Hyperemesis Syndrome in the Emergency Department

(1-178) Evaluating the impact of pharmacists within a multiprofessional lecanemab workgroup

(1-179) Evaluation and Comparison of Pharmacy Intervention Models within a Comprehensive Geriatric Assessment Multidisciplinary Team

(1-180) Evaluation of Long-Acting Sulfonylureas for Type 2 Diabetes (DM2) Management in Elderly Veterans

(1-181) Evaluation of the Safety Outcomes of Buprenorphine in the Elderly

(1-182) Impact of Vitamin B12 Discontinuation After Repletion Within a Veterans Affairs Healthcare System

(1-183) Implementation and Impact Assessment of a Pharmacy Led Geriatrics Clinic

(1-184) Medication Use Evaluation (MUE) for the Use of Drugs with Anticholinergic Properties in Short-Term Rehabilitation Patients

(1-185) Pharmacist-Led Deprescribing Service for Medications with Potential for Cognitive Impairment in Older Adults Referred to Memory Clinic at the Boise VA Medical Center

(1-186) Safety of Sodium Glucose Cotransporter-2 Inhibitor Therapy in Frail Older Veterans with Type 2 Diabetes Mellitus

(1-187) Utilizing the VIONE Dashboard to identify the impact of deprescribing in older adults

(1-188) Impact of Continuous Blood Glucose Monitoring (CGM) on Management of T2DM in HBPC Patients at Captain James A. Lovell Federal Health Care Center (FHCC).

(1-189) Allergy to Beta-Lactam Evaluation

(1-190) Antibiotic prophylaxis given for permanent pacemaker procedures in the Veteran population

(1-191) Are Male UTI Necessarily Different? A retrospective cohort study of male, lower UTI at VHA Puget Sound

(1-192) Evaluation of Extended Interval Antibiotics (Beta-Lactams) in Critically Ill Patients

(1-193) Assessment of Procalcitonin in the Modification of Antibiotic Therapy and Length of Hospital Stay: A Retrospective Analysis

(1-194) Characterization of the use of Truvada and Descovy for Pre-exposure Prophylaxis at the Veterans Affairs Maryland Health Care System

(1-195) Clinical Evaluation of Cefepime and Meropenem Extended Infusion Dosing Strategy: a Retrospective Cohort Study

(1-197) Comparison of Response to Doxycycline Versus Penicillin G Benzathine for Treatment of Syphilis

(1-198) Comparison of third-generation cephalosporins vs fluoroquinolones or trimethoprim-sulfamethoxazole for oral step-down treatment of Enterobacterales bacteremia

(1-199) COVID-19 Rebound in Veterans Taking Nirmatrelvir/Ritonavir or Molnupiravir

(1-200) Decreasing Inappropriate Antipseudomonal Prescribing for Diabetic Foot Infections Through Order Set Implementation at the Orlando Veterans Affairs Healthcare System

(1-201) Engaging Female Veterans in Sexually Transmitted Infection Care: An Interdisciplinary Pilot Using a Clinical Dashboard

(1-202) Evaluating the Appropriateness of HIV Pre-Exposure Prophylaxis (PrEP) Prescriptions and Adherence to Sexually Transmitted Infection (STI) Screening

(1-203) Evaluating the impact of provider-focused interventions on antibiotic prescribing practices for acute respiratory infections

(1-204) Evaluation of a Pharmacy-Based Sexually Transmitted Infection Test-to-Treat Clinic on Increasing STI Testing Rates at an Indian Health Service Facility

(1-205) Evaluation of antibiotic prophylaxis for surgical procedures at the Bay Pines Veterans Affairs Healthcare System (VAHCS)

(1-206) Evaluation of Doxycycline Outpatient Prescribing at a Veterans Affairs Medical Center

(1-207) Evaluation of Infections in Adults Undergoing Cystoscopy with Tailored Preoperative Antibiotic Prophylaxis vs. Standard Prophylaxis

(1-208) Evaluation of Microbiological Differences in COPD Microbiome in Rural versus Urban Populations

(1-209) Evaluation of the Impact of Nirmatrelvir/ritonavir Prescribing on the Development of Post-Acute Sequelae of COVID-19 in Veterans

(1-210) Impact of a Urine Culture Timeout Note on Rate of Urine Cultures Resulted

(1-211) Impact of Antimicrobial Stewardship on Outpatient Antibiotic Prescriptions at the Hershel "Woody" Williams VAMC

(1-212) Impact of Climate Variability on Sputum Microbiota from Patients Hospitalized with a Chronic Obstructive Pulmonary Disease Exacerbation

(1-213) Impact of Implementing a Required Indication-based Urinary Tract Infection (UTI) Diagnostic Order Menu at a Veterans Affairs Facility

(1-215) Implementation and assessment of the Allergy to Beta-Lactam Evaluation (ABLE) program at a Veterans’ Administration Hospital

(1-216) Implementation of Allergy to Beta Lactam Evaluation (ABLE) Template during medication reconciliation at the Minneapolis VA Health-Care System

(1-217) Implementation of Updated Intravenous Vancomycin Dosing Procedure for VA Black Hills Health Care System Pharmacists

(1-218) Improving Antibiotic Stewardship Through Penicillin Allergy Verification in a Rural Setting

(1-219) Leveraging a National Clindamycin Shortage to Revise Institutional Peri-operative Antimicrobial Prophylaxis Guidelines and Decrease Peri-operative Clindamycin Use

(1-220) Leveraging Natural Language Processing to Identify Veterans Who Inject Drugs to Assess Pre-Exposure Prophylaxis and Sexually Transmitted Infection Testing Services at the Veterans Health Administration

(1-221) Optimizing the Use of Statin Therapy for Primary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) in Veterans Living with Human Immunodeficiency Virus (HIV)

(1-222) Pharmacist-driven Allergy to Beta-Lactam Evaluation (ABLE) in the Emergency Department

(1-223) Piperacillin-Tazobactam Medication Use Evaluation

(1-224) Pre-Exposure Prophylaxis Prescribing Practices Within a Veterans Affairs Healthcare System

(1-225) Real-world utilization with ceftolozane/tazobactam among patients admitted to a Veteran Affairs Medical Center

(1-226) The Effect of Outpatient Clinical Treatment Pathway Implementation for Skin and Soft Tissue Infections (SSTIs) on Antibiotic Use and Prescribing

(1-227) Trends in Epidemiology and Predictors of Poor Outcomes for Candida auris and Other Multiple-Drug Resistant Candida species Across Medical Centers in the Veterans Health Administration

(1-228) Utilization of a HIV Pre-Exposure Prophylaxis Dashboard to Increase the Prescribing of Pre-Exposure Prophylaxis for At-Risk Veterans

(1-229) Analysis of Glucagon-Like Peptide-1’s on Diabetes Measures Compared to Yearly Government Performance and Results Act (GPRA) Data in a Rural American Indian Population

(1-230) Assessing the Impact of Short-term App-based Intervention on Long-term Compliance and Patient Outcomes in Veterans with Uncontrolled Non-insulin Dependent Diabetes: a Mixed Methods Follow-up Study

(1-231) Evaluating Medication Reconciliation for Veterans Receiving Self-Directed Care at a Local Community Hospital Before and After the Implementation of a Shared Electronic Medical Record

(1-232) Hurry up and Wait: Optimizing Workflow in Military Pharmacy to Reduce Patient Wait Times

(1-233) Artificial intelligence in oncologic pharmacy: Innovation in toxicity analysis and prescription validation

(1-234) POWER BI®: Decision suppot for the efficient and safe use of pharmacotherapy in chronic migraine

(1-235) Comparison of Total Iron Replenishment with Ferric Carboxymaltose to Other IV Iron Products

(1-236) Optimization of the IV Push Route of Medication Administration Across the Crow Service Unit, a Rural, Critical Access Hospital, Isolated Hardship Location

(1-237) Effect of Prophylactic Electrolyte Supplementation on Refeeding Syndrome for Patients Initiated on Parenteral Nutrition

(1-238) Enhancing Care Coordination for Weight Loss Among Native American Type 2 Diabetic Patients Using Weight-Management Medications

(1-239) Risk Factors for the Development of Acute Kidney Injury in Veterans on Parenteral Nutrition

(1-240) Comparison of Progression Free Survival (PFS) in Patients with Prostate Cancer Receiving Oral Therapy to Those in Literature at Cincinnati Veterans Affairs Medical Center (CVAMC)

(1-241) Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy in Select Chronic Myeloid Leukemia (CML) Patients Within Veterans Integrated Services Network (VISN) 21

(1-242) Evaluation of Buprenorphine Buccal Film and Transdermal Patch in the Treatment of Malignant Pain

(1-243) Evaluation of Neuropathic Pain Management for the Treatment of Malignant Pain

(1-244) Evaluation of Oral Antineoplastic Utilization, Adherence, and Safety in the Veteran Population at a Veterans Affairs Healthcare Center

(1-245) Examining the Utilization of Molecular Testing in Non-Small Cell Lung Cancer at a Single VA

(1-246) Impact of a Pharmacist-Driven Hypertension and Hand-Foot Skin Reaction Monitoring Program in Veterans Receiving Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGF-TKIs) [PHARM-V]

(1-247) Impact of Melphalan Administration With or Without a Day of Rest on Engraftment Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

(1-248) Implementation and Evaluation of a Pharmacist-Led Pain Management Service within a Veterans Affairs Oncology Clinic

(1-249) Multicenter Analysis of Pharmacogenomic-Guided Fluoropyrimidine Chemotherapy Dosing

(1-250) Relugolix Use Evaluation for Advanced Prostate Cancer at Veterans Integrated Services Network 1

(1-251) The Use of Bone Targeting Agents in Patients with Bone Metastasis due to Solid Tumors

(1-252) Assessing Clinician Compliance with the Office of the Inspector General (OIG) Recommended Follow-up for Long-Term Opioid Therapy

(1-253) Evaluating and improving the utility of recommendations from Comprehensive Addiction and Recovery Act interdisciplinary team reviews

(1-254) Evaluation of Multimodal Analgesia Utilization in Patients Admitted to General Medicine at VA Providence Healthcare System with Acute Pain Receiving Oral Opioids

(1-255) Evaluation of opioid pain management plans at discharge for patients with patient-controlled analgesia during hospitalization

(1-256) Implementation of an Updated Buprenorphine Order Set for Emergency Department Management of Opioid Withdrawal

(1-257) Implementation of Naloxone Dispensing by Outpatient Clinical Pharmacists at a Rural Veterans Affairs Medical Center

(1-258) Naloxone Standing Order: Impact of Academic Detailing on Naloxone Distribution and Overdose Education for Outpatient Pharmacists

(1-259) Optimization of Emergency Department Opioid Prescribing at Columbia Veteran Affairs Health Care System

(1-260) Optimizing Naloxone Outreach via Process Improvement Through the Utilization of Pharmacy Interns

(1-261) Overcoming Barriers to Pharmacists Prescribing Naloxone

(1-262) Perioperative Pharmacist Intervention in Surgical Pain Management: Total Knee Arthroplasty and Total Hip Arthroplasty

(1-263) Process Improvement of the Transition of Stable Patients on Medications for Opioid Use Disorder from Substance Use Disorder Clinic to Primary Care Providers

(1-264) Utilization of AudioCARE Automated Phone Program for Naloxone Outreach to High-Risk Veterans at the Bay Pines VA Healthcare System

(1-265) Utilization of Buprenorphine Buccal Film Dosing Frequency in the Setting of Chronic Pain Management – A Single-Center Retrospective Review

(1-266) Effects of the implementation of pharmacogenomics (PGx) testing on the statin tolerability of Veterans within the VA Healthcare System

(1-267) Evaluation of pharmacist led pharmacogenomics testing in patients newly started on clopidogrel using national VA dashboard

(1-268) Impact of comprehensive pharmacogenetic medication review on prescribing at the Boise VA Medical Center (VAMC)

(1-269) Implementation of the Pharmacogenomic Testing for Veterans (PHASER) Program Among High Suicide-Risk Veterans: A Quality Improvement Project

(1-270) Pharmacogenomic Testing for Statin-Associated Musculoskeletal Symptoms within Primary Care

(1-271) Pharmacogenomics Guided Clopidogrel Utilization in Veterans Undergoing Peripheral Arterial Intervention with Vascular Surgery Compared to Usual Care

(1-272) Pharmacogenomics Testing for Veterans (PHASER) at James A. Haley Veterans’ Hospital: Integrating Testing into Pharmacists’ Practice

(1-273) Retrospective Analysis of AUC/MIC Guided Treatment vs. Trough-Based Monitoring to Optimize Vancomycin Dosing

(1-274) The Effect of Pharmacogenetic Testing on Lipid-Lowering Medication Prescribing in Statin-Intolerant Patients at Risk of ASCVD

(1-275) The Impact of Pharmacogenomic Testing in a Rural Mental Health Population

(1-276) To Increase Pre-emptive PGx Testing Through Academic Detailing Visits with Clinicians and Veteran Socialization Strategies

(1-277) Utilization of Pharmacogenomics Testing in the Management of Depression and Anxiety in Primary Care at Two Different VA Facilities

(1-278) Evaluating the Impact of Clinical Pharmacy Technician on New Patient Medication Reconciliations in Primary Care at VA Sierra Nevada Medical Center

(1-280) Antidepressant Use in Patients with Bipolar Disorder with and without Post-Traumatic Stress Disorder

(1-281) Assessing Adherence and Barriers to Long-Acting Injectable Antipsychotics at the Iowa City VA Health Care System

(1-282) Assessing the Impact of a Resident-led Naloxone Outreach Service at the VA Illiana Health Care System

(1-283) Assessing the Utility of Pharmacogenomic Testing to Guide Antidepressant Treatment

(1-284) Blood Pressure and Urine Toxicology Monitoring in Veterans on Prescription Stimulants

(1-285) Bupropion Prescribing Patterns at a Large VA Medical Center

(1-286) Characterization of the Esketamine Clinic for Veterans with Treatment Resistant Depression at VA Maine Healthcare System

(1-287) Comparing Safety of Extended-Release Buprenorphine Formulations for Veterans with Opioid Use Disorder

(1-288) Comparing Treatment Outcomes of Methadone versus Long-Acting Injectable Buprenorphine in Opioid Use Disorder

(1-289) Effects of Injectable Calcitonin Gene-Related Peptide-Antagonists on Migraine-Associated Cost Burden

(1-290) Establishment of an Outpatient Alcohol Use Disorder Clinic: Enhancing Veteran Care through Integrated Pharmacotherapy

(1-291) Evaluating the Efficacy and Safety of Intravenous Ketamine for Treatment-Resistant Depression at a Veterans Affairs Medical Center

(1-292) Evaluating the Impact of Pharmacogenomic Testing on Mental Health Clinical Practice in a Metropolitan Veteran Population

(1-293) Evaluation of adherence to criteria for use for long-acting injectable antipsychotic prescribing within a Veterans Affairs healthcare system

(1-294) Evaluation of Naloxone Kits Prescribed to Veterans Diagnosed With Stimulant Use Disorder at the Miami Veterans Affairs Healthcare System

(1-295) Evaluation of Naltrexone and Bupropion Therapy in Patients with Stimulant Use Disorder After Acute Inpatient Psychiatric Admission

(1-296) Evaluation of Outcomes for Veterans with Opioid Use Disorder Managed by a Clinical Pharmacist Practitioner

(1-297) Evaluation of the Distribution of Naloxone kits in Patients Diagnosed with Opioid Use Disorder at the Miami Veterans Administration (VA) Healthcare System

(1-298) Evaluation of the use of Cognitive Reassessment Monitoring for Outpatient Dementia Medication Prescriptions for Patients in a Veterans Affairs (VA) Healthcare System

(1-299) Impact of a Clinical Pharmacist on the Appropriateness of Prescription Stimulant Monitoring

(1-300) Impact of Letter Campaign on Alcohol Use Disorder Pharmacotherapy Utilization

(1-301) Impact of Pharmacogenomics Testing on Medications for Veterans with Depression

(1-302) Implementation of a pharmacist-managed medication group education series for Residents in a Posttraumatic Stress Disorder Residential Recovery Program at a Veteran Affairs Healthcare System

(1-303) Implementing Contingency Management Attendance for Alcohol Use Disorder in a Pharmacist-Led Outpatient Alcohol Educational Group

(1-304) Improving Migraine and Headache Management: The Role of Pharmacist-Led Education in Enhancing Patient Outcomes

(1-305) Initiative To Improve Lithium Safety Monitoring at Veterans Affairs Medical Center

(1-306) Inpatient Buprenorphine Micro-Induction Dosing via New Protocol - Continuous Quality Improvement Evaluation

(1-307) Lifting second generation antipsychotic order restrictions on acute care units in a Veterans Affairs hospital

(1-308) Long-Acting Injectable Antipsychotic Medication Use Evaluation at Veterans Affairs of Connecticut Healthcare System

(1-309) Management of Severe Hyperglycemia Secondary to Clozapine Initiation for Schizoaffective Disorder

(1-310) Monitoring for Tardive Dyskinesia in Antipsychotic-Treated Patients

(1-311) Monitoring Pharmacogenomic Interventions in the Mental Health Setting at a Veterans Affairs Hospital

(1-312) Pharmacist Utilization of a Note Template for Documenting Pharmacogenomic Medication Recommendations at the Minneapolis Veterans Affairs Health Care System (MVAHCS)

(1-313) Pharmacy Intervention to Improve Monitoring in Patients Taking Second Generation Antipsychotics

(1-314) Retrospective Review of Appropriate Non-Formulary Antidepressant Usage at a Veterans Affairs Medical Center (VAMC)

(1-315) Retrospective Review of Dual CGRP Targeted Treatment Regimens for Acute and Preventive Treatment of Migraines

(1-316) Retrospective Review of Intramuscular Naltrexone Adherence at the Stratton VA Medical Center

(1-317) Retrospective Study of Neuropsychiatric Hospitalizations in Patients Receiving Montelukast vs. Loratadine for Allergic Rhinitis in a Veterans Affairs Population

(1-318) Standardization of Long-Acting Injectable Antipsychotic Administration at VA Puget Sound Health Care System

(1-320) Implementation of Pharmacy Technicians within Population Health to Identify Patients on COPD Dashboard for Pharmacist Intervention

(1-321) Pharmacist-Led Home Visits to Implement Point-of-Care A1c Testing and Re-Establish Care for Patients Lost to Follow-Up

(1-322) A retrospective evaluation of antibiotic utilization in non-critically ill hospitalized patients with an acute exacerbation of COPD (AECOPD) with or without procalcitonin (PCT).

(1-323) An Evaluation of a Clinical Decision Support Tool Implemented at the Phoenix VA Health Care System

(1-324) Assessing Impact of an After-Hours Vancomycin Dosing Policy on Proportion of Veterans Receiving Timely Vancomycin Administration

(1-325) Assessing multimodal analgesia in post-operative surgery patients

(1-327) Assessment of Omnicell® Utilization at the Cincinnati VAMC Outpatient Clinics: Safety Review and Implementation of Best Practices

(1-328) Completion of annual preventative diabetic foot examinations at routine primary care visits in T2DM patients prescribed empagliflozin at a Department of Veterans Affairs Medical Center

(1-329) Evaluating the Efficacy and Safety of Phenobarbital Protocol for Treatment of Alcohol Withdrawal Syndrome

(1-330) Evaluating the Impact of Clinical Pharmacy Technicians on Population Health Metrics and the Effect on Clinical Pharmacy Practitioner Utilization at VA Maine Healthcare System

(1-332) Evaluation of a Clinical Pharmacist-Led Service to Facilitate Transitions of Care for COPD within an Integrated VA Healthcare System

(1-333) Evaluation of a Pharmacist-led Pharmacogenomic Service at VA Puget Sound

(1-334) Evaluation of Pneumococcal Vaccination and Boosting Practices in Immunocompromised Veterans at VA Sierra Nevada Health Care System

(1-335) Evaluation of the Timing of Anticoagulation after Thrombolytic Therapy Administration for the Treatment of Frostbite at Alaska Native Medical Center

(1-336) Evaluation of the Use of Continuous Glucose Monitoring (CGM) in VA Greater Los Angeles (VAGLA) Patient Aligned Care Team (PACT) Clinics

(1-337) Impact of Alcohol Interventions in Veterans Receiving Treatment for Chronic Pain at the Carl Vinson VA Medical Center (CVVAMC)

(1-338) Impact of Drug Shortages on Cost and Workload at the Cincinnati Veterans Affairs Medical Center Pharmacy

(1-339) Impact of Pharmacist-led Education of Inhaler Technique to Acute Care Nurses

(1-340) Implementation of a Syringe Services Program: a Harm Reduction Strategy

(1-341) Implementing a Transitions of Care Program to Reduce Readmissions Among Patients with Heart Failure at the Veterans Affairs Caribbean Healthcare System

(1-342) Improving Detection, Assessment, and Reporting of Inpatient Adverse Drug Reactions

(1-343) Improving Prescription Drug Monitoring Program Checks

(1-344) Increasing Naloxone Distribution for Veterans At Risk for Opioid-related Overdose

(1-345) Medication Use Evaluation and the Impact of Enhanced Safety Monitoring in Testosterone Therapy for Men: Retrospective Assessment of Utilization

(1-346) Optimizing Workflow for Urgent Medication Mail Orders: A Process Improvement Initiative

(1-347) Outpatient Pharmacy Local Prescription Mailing- Quality Improvement and Patient Safety Project

(1-348) Quality Improvement of Pain Management within the Patient-Centered Medical Home Model for American Indian Alaska Native Patients: Integrating Pharmacist-Led Pain Management Services

(1-349) Quality Improvement Project In-Progress: Standardizing Orders and Documentation of Long Acting Injectable (LAI) Administration in the Mental Health (MH) Outpatient Setting

(1-350) Determination of Maximum Daily Doses for Topical Drug Products

(1-351) Review of Adverse Effects Associated with Empagliflozin Use at the Oklahoma City Veterans Affairs Health Care System: A Quality Improvement Evaluation Project

(1-352) Risk of Intestinal Obstruction Associated with Semaglutide: A Retrospective Study

(1-353) Hydroxyurea Interference with Certain Continuous Glucose Monitoring Systems: An FDA Safety Evaluation and Implications for the Practicing Pharmacist

(1-354) Vancomycin Use and Safety Outcomes of Current Trough-Based Monitoring at Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS)

(1-355) Implementation of a Labor and Delivery Epidural Service in a Rural Healthcare Facility: One Year Later

(1-356) Deprescribing High Risk/Unneeded Medications Prescribed during Hospitalization

(1-357) Impact of Pharmacist Intervention on Laboratory Monitoring for Methotrexate Patients

(1-358) Turning the Corner - Utilization of Letermovir for Cytomegalovirus Prophylaxis in Allogeneic Stem Cell Transplant in the Veteran Population

(1-359) Utilization of Pharmacogenetic Data to Evaluate Tacrolimus Dosing Needs Following Discontinuation of an Azole Antifungal

(1-360) Vaccine-Induced Modulation of Panel reactive Antibodies: Consequences on Transplant Candidacy (Vaccine IMPACT)

(1-361) Assessing the Impact of Patient Health Questionnaire-9 and General Anxiety Disorder-7 Monitoring in Outpatient Depression and Anxiety

(1-362) Increasing Equity in Mental Health Veterans through Pharmacogenomics

(1-363) Pharmacist Implementation and Delivery of a Single-Session Pain Management Skills Intervention at a Large Veterans Affairs Health Care System

(1-364) Prospective Review on Whole Health Practice and Their Impact on Burnout Levels in a VA Pharmacy Residency Program

(1-365) Appropriate Prescribing of Calcium and Vitamin D in Women with Osteoporosis or Osteopenia

(1-366) Clinical Pharmacist-Led Improvement of Osteoporosis Screening and Management in Roseburg VA Health Care System

(1-367) Contraception on Demand, Increasing Patient Access to Contraceptives Within the Gulf Coast Veterans Health Care System

(1-368) Evaluating the impact of a pharmacist-driven osteoporosis screening and treatment program in women veterans at the Birmingham VA Medical Center

(1-369) Evaluation of a Pharmacist-Led Health Disparity Initiative to Address Statin Therapy in Female Patients at the Miami VA Healthcare System

(1-370) Evaluation of Long-Term Use of Oral Bisphosphonates Therapy in the Female Veteran Population at VA Caribbean Healthcare System

(1-371) Impact of Pharmacist-Led Preconception Counseling Service in a Veterans Affairs Women's Health Clinic

(1-372) Increasing Access to Pharmacy Clinical Services within a Women’s Health Clinic Population at an Indian Health Service Facility.

(1-373) Medication Use Among Pregnant and Child-Bearing Age Veterans at the Jesse Brown VA Medical Center

(1-374) Reducing Gender Disparities in Blood Pressure Control Among Female Veterans with Type II Diabetes Mellitus